MARY HARDING: Open Payments
NPI 1730722125 · MOORESVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,379 in 95 payments from 14 companies in 2025. Trend: 2023 $451 · 2024 $741 · 2025 $1,379
Food & beverage: $1,372Education: $8
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 15 | $221 |
| Alkermes, Inc. | 19 | $211 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $197 |
| Axsome Therapeutics, Inc. | 13 | $184 |
| Vanda Pharmaceuticals Inc. | 8 | $148 |
| Neurocrine BioSciences, Inc. | 5 | $88 |
| E.R. Squibb & Sons, L.L.C. | 4 | $72 |
| ABBVIE INC. | 3 | $63 |
| Corium, LLC | 4 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $41 |
Products named: CAPLYTA, Auvelity, ARISTADA, FANAPT, REXULTI, INGREZZA, COBENFY, VRAYLAR.
Industry payments across IN — which companies pay providers there.
